Sartorius, DE0007165631

RBC keeps EUR 220 target for Sartorius stock

Published on 10/12/2026 at 10:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached EUR 911.80 million, up 3.11 percent year on year. Sartorius stock is EUR 253.40 on October 12, 2026, versus EUR 253.00.

Key points in brief

  • RBC keeps Sartorius at Sector Perform with a EUR 220.00 target dated October 5, 2026.
  • Second-quarter 2026 revenue reached EUR 911.80 million, up 3.11 percent year on year.
  • Sartorius traded at EUR 253.40 at Lang & Schwarz on October 12, 2026, 0.16 percent above the October 9 Xetra close of EUR 253.00.
  • Third-quarter results are scheduled for October 22, 2026, with fiscal 2026 sales guidance of 5 to 9 percent growth in constant currencies.
Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern
Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius (ISIN DE0007165631) traded at EUR 253.40 at Lang & Schwarz on October 12, 2026 at 10:48 a.m. CEST, 0.16 percent above the Xetra close of October 9, 2026 at EUR 253.00. The latest analyst signal came from RBC, which kept its Sector Perform rating and EUR 220.00 price target on October 5, 2026, according to FinanzNachrichten.

Three dated analyst signals

Barclays raised its Sartorius target from EUR 300.00 to EUR 310.00 on September 30, 2026, while keeping its Overweight rating, as reported by FinanzNachrichten. Goldman Sachs lifted its target from EUR 228.00 to EUR 244.00 on September 30, 2026, while retaining Neutral, according to FinanzNachrichten. RBC then kept its EUR 220.00 target and Sector Perform rating on October 5, 2026.

What does the next report test?

Sartorius is scheduled to publish third-quarter results on October 22, 2026, and its fiscal 2026 sales guidance remains 5 to 9 percent growth in constant currencies, according to the company's Sartorius investor-relations page. The date gives the market a clear test of whether the recovery reflected in recent analyst targets is reaching reported operations.

Second-quarter 2026 revenue was EUR 911.80 million, compared with EUR 884.30 million in the second quarter of 2025, a 3.11 percent increase. Adjusted earnings per share rose to EUR 0.95 from EUR 0.47 over the same comparison, according to IT BOLTWISE on September 23, 2026. The combination of revenue growth and faster earnings-per-share growth makes the October report important for judging operating leverage, not just demand.

Stock stays below its yearly high

The current EUR 253.40 quote is EUR 18.50 below the 52-week high of EUR 271.90 and EUR 54.90 above the 52-week low of EUR 198.50, with market capitalization at EUR 17.5 billion as of October 12, 2026. The modest 0.16 percent premium to the October 9 Xetra close leaves the analyst debate centered on execution against the October reporting date rather than on a large same-day move. The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.

Sartorius stock facts

  • Company: Sartorius AG
  • ISIN: DE0007165631
  • WKN: 716563
  • Ticker: SRT3
  • Primary exchange: Xetra
  • Price Lang & Schwarz as of October 12, 2026 at 10:48 a.m. CEST: EUR 253.40
  • Change versus Xetra close: plus 0.16 percent
  • Xetra close October 9, 2026: EUR 253.00
  • Market capitalization: EUR 17.5 billion (as of October 12, 2026)
  • 52-week range: EUR 198.50-EUR 271.90 (as of October 12, 2026)
  • Sector / Industry: Healthcare / Medical Instruments and Supplies
  • Index membership: MDAX
  • Next earnings date: October 22, 2026

Market context: Market report DAX.

More news and analyses on Sartorius stock

Disclaimer...

en | DE0007165631 | SARTORIUS | boerse | 70299414 | bgmi